Global Dementia Drugs and Companies Pipeline Review H2 2016

PUNE, INDIA, September 12, 2016 /EINPresswire.com/ -- Summary
‘Dementia - Pipeline Review, H2 2016’, provides an overview of the Dementia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.

Complete report details @ https://www.wiseguyreports.com/reports/636757-dementia-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Request a sample report @ https://www.wiseguyreports.com/sample-request/636757-dementia-pipeline-review-h2-2016

Scope
- The report provides a snapshot of the global therapeutic landscape of Dementia
- The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects
- The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Dementia
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dementia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/636757-dementia-pipeline-review-h2-2016

Key points in table of content
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Dementia Overview 10
Therapeutics Development 11
Pipeline Products for Dementia - Overview 11
Pipeline Products for Dementia - Comparative Analysis 12
Dementia - Therapeutics under Development by Companies 13
Dementia - Therapeutics under Investigation by Universities/Institutes 16
Dementia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Dementia - Products under Development by Companies 21
Dementia - Products under Investigation by Universities/Institutes 25
Dementia - Companies Involved in Therapeutics Development 26
Adamas Pharmaceuticals, Inc. 26
AgeneBio Inc. 27
Alector LLC 28
AlzProtect SAS 29
Amarantus Bioscience Holdings, Inc. 30
Anavex Life Sciences Corp. 31
Axon Neuroscience SE 32
Axovant Sciences Ltd. 33
BioArctic Neuroscience AB 34
Biogen Inc 35
Biotie Therapies Corp. 36
Boehringer Ingelheim GmbH 37
Chase Pharmaceuticals Corporation 38
Cortice Biosciences, Inc. 39
Daewoong Pharmaceutical Co., Ltd. 40
Eisai Co., Ltd. 41
Eli Lilly and Company 42
FORUM Pharmaceuticals Inc. 43
H. Lundbeck A/S 44
Heptares Therapeutics Limited 45
Hyundai Pharmaceutical Co., Ltd. 46
Ildong Pharmaceutical Co., Ltd. 47
Immungenetics AG 48
ImStar Therapeutics Inc. 49
Integrative Research Laboratories Sweden AB 50
Intellect Neurosciences, Inc. 51
Intra-Cellular Therapies, Inc. 52
INVENT Pharmaceuticals, Inc. 53
M3 Biotechnology, Inc. 54
MediPost Co., Ltd. 55
Neuraltus Pharmaceuticals, Inc. 56
Neurimmune Holding AG 57
Neurodyn Inc. 58
Oryzon Genomics SA 59
Otsuka Holdings Co., Ltd. 60
P2D Bioscience 61
Pacific Northwest Biotechnology, LLC 62
Pivot Pharmaceuticals Inc 63
Sinil Pharmaceutical Co., Ltd 64
Stelic Institute & Co., Inc. 65
Sumitomo Dainippon Pharma Co., Ltd. 66
Sylentis S.A.U. 67
Takeda Pharmaceutical Company Limited 68
TauRx Therapeutics Ltd. 69
Voyager Therapeutics, Inc. 70
WhanIn Pharmaceutical Co., Ltd. 71
Zhejiang Hisun Pharmaceutical Co., Ltd. 72
Dementia - Therapeutics Assessment 73
Assessment by Monotherapy Products 73
Assessment by Combination Products 74
Assessment by Target 75
Assessment by Mechanism of Action 78
Assessment by Route of Administration 81
Assessment by Molecule Type 83
Drug Profiles 85
(donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 85
(donepezil hydrochloride + solifenacin succinate) - Drug Profile 87
AADvac-1 - Drug Profile 88
AD-35 - Drug Profile 89
ANAVEX-371 - Drug Profile 90
Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 92
ASN-561 - Drug Profile 93
AVP-786 - Drug Profile 94
AZP-2006 - Drug Profile 97
BAN-0805 - Drug Profile 99
BI-409306 - Drug Profile 100

Buy this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=636757

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
16468459349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.